Interleukin 6 (IL-6) is a cytokine that is produced by a wide variety of cells and has pleiotropic biological functions, such as the induction of acute phase proteins in hepatocytes, the terminal differentiation and growth promotion of B cells, the differentiation and activation of T cells and macrophages, and the regulation of expression of other cytokines (1). IL-6 has been implicated in the pathology of several diseases, and its role in inflammation, viral infection, autoimmunity, and cancer has been reviewed recently (1, 2) .
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Serum IL-6 increases markedly in many pathological conditions, and its accurate and precise determination in biological fluids is of great importance for the early diagnosis of many diseases (3) (4) (5) (6) (7) . Measurement of IL-6 in biological fluids is mainly based on bioassays and immunoassays (8 -13) . The presence of natural compounds known to bind IL-6 in biological fluids (14 -18) and the effect of preanalytical factors (19) , as well as the use of an internationally accepted IL-6 standard preparation (20 -21) , is of great importance for the performance of IL-6 immunoassays.
Here we describe a highly sensitive enzyme immunoassay for the determination of IL-6 in serum and plasma, based on the enzyme-amplified lanthanide luminescence (EALL) detection approach (22) (23) (24) (25) . An ultra-low detection limit is obtained by the powerful detection system that is based on the combination of enzymatic amplification introduced by the enzyme alkaline phosphatase (ALP) and the formation of a highly fluorescent terbium complex (26, 27) , which is monitored by time-resolved or conventional fluorometry.
A monoclonal antibody (anti-IL-6, CLB IL-6/16) and a biotinylated goat polyclonal antibody against human IL-6 were kindly donated by Prof. L. Aarden (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands). The IL-6 stock solution (100 g/L) was prepared by dissolving the lyophilized human recombinant IL-6 international standard, 88/514 (National Institute of Biological Standards and Controls), in 10 g/L bovine serum albumin, in a 50 mmol/L Tris buffer, pH 7.40, containing 0.5 g/L NaN 3 and 9 g/L NaCl, and was kept in aliquots at Ϫ20°C. IL-6 calibrators at a concentration range of 1-2000 ng/L were prepared by appropriate dilutions of the IL-6 stock solution in assay buffer and in IL-6-free plasma. Coating, wash, and blocking solutions and the substrate buffer of ALP were prepared as described previously (25) . Assay buffer was 60 g/L bovine serum albumin in 50 mmol/L Tris buffer, pH 7.40, containing 0.5 g of NaN 3 , 9 g of NaCl, 50 mL of mouse serum, and 50 mL of goat serum per liter. Developing solution was 0.100 mol/L 3-[cyclohexy-lamino]-1-propanesulfonic acid, pH 12.60, containing 3 mmol/L Tb 3ϩ and 3 mmol/L EDTA. The phosphate ester of diflunisal (DIFP) stock solution (10 mmol/L) was prepared in 0.1 mol/L NaOH and kept at 4°C, whereas the DIFP working solution (500 mol/L) was prepared just before use by a 20-fold dilution of the stock solution in ALP substrate buffer (23) .
For serum, blood samples were collected in clean glass tubes, left at room temperature for 1 h, and centrifuged at 4°C. For plasma, blood samples were collected in EDTAcontaining Vacutainer Tubes (Becton Dickinson) and centrifuged at 4°C. Serum and plasma samples were stored at Ϫ20°C until assayed. All samples were kindly provided by Dr. E. P. Diamandis (Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada).
A typical "sandwich type" immunoassay was used. Assay conditions involving all steps, such as antibody concentrations and incubation times, were optimized in respect to the best signal-to-noise ratios, sensitivity, and rapidity. The final optimized assay protocol was the following: (a) immobilization of the anti-IL-6 monoclonal (stock solution, 1 g/L), diluted 400-fold (100 L/well) in coating solution, overnight, wash; (b) blocking with blocking solution (200 L/well) for 2 h, wash; (c) addition of the analyte (100 L/well) diluted with assay buffer (50 L/well), wash twice (incubation time of 2 h was found to be optimum when time-resolved fluorescence was used as a detection technique, whereas 3.5 h were required to achieve the same sensitivity with conventional fluorescence); (d) addition of the biotinylated anti-IL-6 goat polyclonal antiserum (stock solution, 1 g/L) diluted 3000fold in assay buffer (100 L/well), incubation for 30 min, wash four times; (e) addition of SA-ALP conjugate (stock solution, 1 g/L), diluted 20 000-fold in assay buffer (100 L/well), incubation for 15 min, wash four times; and ( f ) addition of the DIFP working solution (100 L/well), incubation for 30 min. The enzymatic reaction was stopped by adding developing solution (100 L/well). All incubation steps were performed at room temperature.
Time-resolved fluorescence measurements were performed in the Cyber-Fluor 615 Time Resolved Fluorometer/Immunoanalyzer (exc ϭ 337.1 nm, em ϭ 615 nm). Conventional fluorescence measurements were performed in the Perkin-Elmer M 512-A fluorescence spectrophotometer (exc ϭ 284 nm, em ϭ 546 nm). In this case, aliquots of 180 L of the DIF-Tb 3ϩ -EDTA ternary complex, developed finally in each well, and 400 L of developing solution were brought into a 1.00-mL cuvette and mixed thoroughly before measurement.
The calibration curve for IL-6 has a reportable assay range up to 2000 ng/L. However, when IL-6 calibrators were diluted in IL-6-free plasma, the calibration curve gave a 30% lower slope than that obtained by dilutions in assay buffer. This could be explained by the presence of various IL-6 binding proteins (sIL-6R, ␣2-macroglobulin, C-reactive protein) in serum and plasma (14 -18) , which can compete with the assay antibodies for binding to IL-6.
The accuracy of the assay was tested by performing Clinical Chemistry 44, No. 6, 1998 analytical recovery and dilution experiments. To assess analytical recovery, three plasma and three serum samples supplemented with recombinant human IL-6 (rhIL-6) at three different concentrations were assayed before and after the addition of rhIL-6. When IL-6 calibrators were diluted in a pool of IL-6-free plasma, satisfactory analytical recoveries were obtained (Table 1) . Serum dilution experiments showed that both recombinant and native IL-6 are equally recognized by the assay. When we serially diluted three pathological serum samples with high concentrations of IL-6 and one serum sample with rhIL-6, added to a final concentration of 1000 ng/L with a pool of negative control plasmas, the dilution curves were parallel in all cases.
To determine within-run precision of the assay, three serum samples were assayed in six parallel determinations. To determine between-run precision of the assay, aliquots of three serum samples were stored frozen (Ϫ20°C) and analyzed over a period of 2 weeks in three parallel determinations, each in six separate assays. Within-run CVs were 3% to 9% (n ϭ 6) at 10 -100 ng/L, and between-run CVs were 5% to 12% (n ϭ 6 over 2 weeks) at 6 -85 ng/L. The precision profile of the method in assay buffer and serum, as measured by time resolved fluorescence, is shown in Fig. 1 .
The detection limit, defined as the minimal concentration of IL-6 that produces a fluorescent signal equal to the nonspecific background plus 2 SD, was as low as 0.15 ng/L when rhIL-6 calibrators were diluted in assay buffer (n ϭ 12) and 0.5 ng/L when diluted in human plasma (n ϭ 12).
The specificity of the assay is based on the use of well-characterized and selected antibodies (10) . However, when 22 apparently positive sera (IL-6, ϳ20 -10 000 ng/L) were assayed after the addition of mouse and goat serum (5%) to the assay buffer, 12 of them were found to contain markedly lower amounts of IL-6 (1-3 orders of magnitude). Therefore, the addition of mouse and goat serum in the assay buffer was shown to abolish false-positive interferences by rheumatoid factors and heterophilic antibodies, whereas the IL-6 calibration curve or the IL-6positive sera were not affected. These results are in agreement with those reported previously (10) .
The mean serum concentration of IL-6 in 32 apparently healthy individuals was 3.0 ng/L (SD, 2.7 ng/L), whereas the mean serum concentration of IL-6 in 27 patients with various inflammatory diseases was 72 ng/L (SD, 43 ng/L). We compared the results of our assay with those obtained with a commercially available immunoassay for IL-6, Medgenix Diagnostics ELISA. For 21 serum samples from patients with inflammatory diseases and healthy blood donors analyzed by our EALL immunoassay (x) and by Medgenix Diagnostics ELISA (y), the regression equation was: y ϭ 1.48x ϩ 3.4 ng/L, r ϭ 0.948, S y͉x ϭ 23.1. These results indicate that EALL gives lower values for IL-6 than this particular ELISA kit. There is no simple explanation for this, because it has been clearly stated in a recent study (20) that even when the same international standards provided by the National Institute of Biological Standards and Controls were used, a wide variation in IL-6 values was obtained for the same samples when analyzed by several commercial ELISA kits.
In conclusion, the EALL immunoassay for IL-6 in serum demonstrates exceptional sensitivity and a much lower detection limit (ϳ0.5 ng/L in serum) in a very short incubation time (ϳ3 h) in comparison with other immunoassays for IL-6 (8 -13) .
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